Fibrosis in patients with chronic hepatitis C: Detection and significance

Seminars in Liver Disease

Volumn 20, Issue 1, 2000, Pages 47-56

  Poynard, Thierry ^a   Ratziu, Vlad ^a   Benmanov, Yves ^a   Di Martino, Vincent ^a   Bedossa, Pierre ^b   Opolon, Pierre ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

Fibrosis; HCV; Liver biopsy; Ribavirin

Indexed keywords

INTERFERON; RIBAVIRIN;

AGE; ALCOHOL CONSUMPTION; ARTICLE; DISEASE COURSE; DISEASE DURATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LYMPHOCYTE COUNT; PRIORITY JOURNAL; RISK FACTOR;

ANTIVIRAL AGENTS; BIOPSY, NEEDLE; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 0033916222     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. WHO. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997;72:341-344
2. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A non-B hepatitis. N Engl J Med 1992;327:1906-1911
3. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332: 1463-1466
4. Darby SC, Ewart DW, Giangrande PLF, et al. Mortality from liver cancer and liver disease in haemophilic men and boys given blood products contaminated with hepatitis C. Lancet 1997;350:1425-1431
5. El-Serag HB, Mason A. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;34:745-750
6. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94 [letter]. Lancet 1997;350:1142-1143
7. Deuffic S, Poynard T, Buffat L, Valleron A-J. Trends in primary liver cancer [letter]. Lancet 1998;351:214-215
8. Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999;29:1596-1601
9. Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832
10. Sobesky R, Mathurin P, Charlotte F, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999; 116:378-386
11. Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997;26:57S-61S
12. Consensus Statement. EASL International Consensus Conference on Hepatitis C. J Hepatol 1999;30:956-961
13. Poynard T, Lebrec D. The inconvenience of investigations used in hepatology: patients' and hepatologists' opinions. Liver 1982;2:369-375
14. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-374
15. Ludwig J. The nomenclature of chronic active hepatitis: an obituary. Gastroenterology 1993;105:274-278
16. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-1519
17. Bedossa P, Poynard T, the METAVIR Cooperative Group. Interand intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994;20;1:15-20
18. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-293
19. Knodell KG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435
20. Wong VS, Wight DG, Palmer CR, Alexander GJ. Fibrosis and other histological features in chronic hepatitis C virus infection: a statistical model. J Clin Pathol 1996;49:465-469
21. Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepatol 1997;4:199-208
22. Paradis V, Mathurin P, Laurent A, et al. Histological features predictive of liver fibrosis in chronic hepatitis C infection. J Clin Pathol 1996;49:998-1004
23. Yano M, Kumada H, Kage M, et al. The long term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-1340
24. Datz C, Cramp M, Haas T, et al. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut 1999;44: 563-567
25. Poynard T, McHutchison J, Davis G, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J, and the FIBROVIRC Project Group. Impact of interferon alfa-2b and ribavirin on the liver fibrosis progression in patients with chronic hepatitis C. Hepatology 1998;28:497A
26. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998;28:805-809
27. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30: 1054-1058
28. von Frerichs. Uber den diabetes. Berlin: Hirschwald, 1884
29. Schupfer F. De la possibilité de faire "intra vitam" un diagnostic précis des maladies du foie et de la rate. Semin Méd 1907;27: 229-230
30. Huard P. La ponction biopsie du foie et son utilité dans le diagnostic des affections hépatiques. Ann Anat Path 1935;12:1118-1124
31. Theodossi A, Spiegelhalter D, Portmann B, Eddleston AL, Williams R. The value of clinical, biochemical, ultrasound and liver biopsy data in assessing patients with liver disease. Liver 1983;3:315-326
32. Soloway RD, Baggenstoss AH, Schoenfield LJ. Summerskill WH. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis 1971;16:1082-1086
33. Theodossi A, Skene AM, Portmann B. Observer variation in assessment of liver biopsies including analysis by kappa statistics. Gastroenterology 1980;79:232-241
34. Pagliaro L, Rinaldi F, Craxi A, et al. Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial. Dig Dis Sci 1983;28:39-43
35. Colombo M, Del Ninno E, de Franchis R, et al. Ultrasound-assisted percutaneous liver biopsy: superiority of the Tru-Cut over the Menghini needle for diagnosis of cirrhosis. Gastroenterology 1998;95:487-489
36. Papini E, Pacella CM, Rossi Z, et al. A randomized trial of ultrasound-guided anterior subcostal liver biopsy versus the conventional Menghini technique. J Hepatol 1991;13:291-297
37. Lindor KD, Bru C, Jorgensen RA, et al. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology 1996;23:1079-1083
38. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986;1:523-525
39. Crawford AR, Lin XZ, Crawford JM. The normal adult human liver biopsy: a quantitative reference standard. Hepatology 1998;28:323-331
40. Urena MA, Ruiz-Delgado FC, Gonzalez EM, et al. Assessing risk of the use of livers with macro and microsteatosis in a liver transplant program. Transplant Proc 1998;30:3288-3291
41. Gayral F, Potier M, Salmon R, Labayle D, Larrieu H. Vascular complications of needle biopsy of the liver. J Chir (Paris) 1979;116:261-264
42. Lebrec D, Goldfarb G, Degott C, Rueff B, Benhamou JP. Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure. Gastroenterology 1982;83:338-340
43. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986;2:165-173
44. McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990;99:1396-1400
45. Maharaj B, Bhoora IG. Complications associated with percutaneous needle biopsy of the liver when one, two or three specimens are taken. Postgrad Med J 1992;68:964-967
46. Van Thiel DH, Gavaler JS, Wright H, Tzakis A. Liver biopsy. Its safety and complications as seen at a liver transplant center. Transplantation 1993;55:1087-1090
47. Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 1993;118:96-98
48. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995;36:437-441
49. Vivas S, Palacio MA, Rodriguez M, Lomo J, Cadenas F, Giganto F, Rodrigo L. Ambulatory liver biopsy: complications and evolution in 264 cases. Rev Esp Enferm Dig 1998;90:175-182
50. Teare JP, Sherman D, Greenfield SM, et al. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 1993;342:895-898
51. Oberti F, Valsesia E, Pilette C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997;113:1609-1616
52. Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997;92:1302-1304
53. Gaiani S, Gramantieri L, Venturoli N, et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol 1997;27:979-985
54. Aube C, Oberti F, Korali N, et al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol. 1999;30:472-478
55. Mathurin P, Moussalli J, Cadranel JF, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998;27:868-872
56. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, Ferreira-Gonzalez A, Mills AS, Garret C. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117:1164-1172
57. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis: Effects of dose and duration. Hepatology 1996;24:778-789
58. Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. J Hepatol 1997;26:1187-1199
59. Capra F, Casaril M, Gabrielli GB, et al. Dolci Alpha-interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers. J Hepatol 1993;18:112-118
60. Fukuda Y, Nakano I, Katano Y, et al. Assessment and treatment of liver disease in Japanese haemophilia patients. Haemophilia 1998;4:595-600
61. Kaplanski G, Farnarier C, Payan MJ, Bongrand P, Durand JM. Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Correlation with cytokine concentrations and liver inflammation and fibrosis. Dig Dis Sci 1997;42:2277-2284
62. Kasahara A, Hayashi N, Mochizuki K, et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J Hepatol 1997;26:574-583
63. Mazzoran L, Tamaro G, Mangiarotti MA, et al. Effects of interferon therapy on fibrosis serum markers in HCV-positive chronic liver disease. Eur J Gastroenterol Hepatol 1998;10:125-131
64. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996;24:759-765
65. Verbaan H, Bondeson L, Eriksson S. Non-invasive assessment of inflammatory activity and fibrosis (grade and stage) in chronic hepatitis C infection. Scand J Gastroenterol 1997;32: 494-499
66. Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepatol 1998;5: 187-192
67. Yamada M, Fukuda Y, Koyama Y, et al. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C. J Gastroenterol Hepatol 1996;11:646-651
68. Yamada M, Fukuda Y, Nakano I, Katano Y, Takamatsu J, Hayakawa T. Serum hyaluronan as a marker of liver fibrosis in hemophiliacs with hepatitis C virus-associated chronic liver disease. Acta Haematol 1998;99:212-216